Rasmussen’s encephalitis: from immune pathogenesis towards targeted-therapy

First described by Theodore Rasmussen in 1958 [1], Rasmussen encephalitis (RE) is defined as “a chronic, progressive encephalopathy with unilateral involvement and featured by intractable focal seizures, Epilepsia Partialis Continua (EPC), hemiparesis and progressive cognitive decline” [2]. the annual incidence is estimated to be about 2.4 cases/107 people under 18 years [3]. Authors do not describe any sex or ethnic predominance [4]. The mean age at presentation is between 6 and 8 years, and the neurologic development at the onset is usually normal [5].